InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,223.70
(
0.21%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: BTH post# 832

Thursday, 07/08/2010 10:37:36 AM

Thursday, July 08, 2010 10:37:36 AM

Post# of 80490

You need to go back and listen to the conference call if it is still online.



Actually, DewDiligence has it right. Here's the exact quote from MRK's R&D presentation in May.

Next slide. Let me now move on to oncology with our mTOR inhibitor, ridaforolimus -- or MK-8669.
Our oncology pipeline, as you know, is relatively young, but it's developing nicely. I'm pleased to say that our mTOR inhibitor
is moving along well, and we anticipate filing it for soft tissue sarcoma this year, pending the results of an interim analysis.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up